Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The interest coverage ratio is -15.31x as of the fiscal period ended Sunday, December 31, 2023.
Reported quarterly interest coverage; no daily interpolation. Q4 FY2023 (2023-12-31): -15.31x.
INTEREST COVERAGE RATIO
-15.31x
INTEREST COVERAGE RATIO AVG TTM
N/A
INTEREST COVERAGE RATIO AVG 3Y
N/A
INTEREST COVERAGE RATIO AVG 5Y
N/A
INTEREST COVERAGE RATIO AVG 10Y
-137.74x
INTEREST COVERAGE RATIO AVG 15Y
-31.39x
INTEREST COVERAGE RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
+88.88%
CURRENT VS 15Y AVG
+51.22%
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-6.38x
median of 528 covered companies
CURRENT VS SECTOR MEDIAN
-140.22%
vs the sector median at left
Celldex Therapeutics, Inc.
Market Cap
$2.07B
Interest Coverage Ratio
-15.31x
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.08B
Interest Coverage Ratio
7.10x
TTM Avg
7.23x
3Y Avg
7.23x
5Y Avg
136.60x
Market Cap
$2.08B
Interest Coverage Ratio
-41.89x
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.07B
Interest Coverage Ratio
-73.44x
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.03B
Interest Coverage Ratio
-0.33x
TTM Avg
467.98x
3Y Avg
502.49x
5Y Avg
502.49x
Market Cap
$2.04B
Interest Coverage Ratio
4.32x
TTM Avg
4.32x
3Y Avg
4.32x
5Y Avg
4.32x
Market Cap
$2.04B
Interest Coverage Ratio
N/A
TTM Avg
166.84x
3Y Avg
166.84x
5Y Avg
166.84x
Market Cap
$2.04B
Interest Coverage Ratio
-3.69x
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | INTEREST COVERAGE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Celldex Therapeutics, Inc. (CLDX) | $2.07B | -15.31x | N/A | N/A | N/A |
| Alvotech (ALVO)vs › | $2.07B | 0.52x | 0.48x | 0.48x | 0.48x |
| Vericel Corporation (VCEL)vs › | $2.08B | 7.10x | 7.23x | 7.23x | 136.60x |
| Vera Therapeutics, Inc. (VERA)vs › | $2.08B | -41.89x | N/A | N/A | N/A |
| Viridian Therapeutics, Inc. (VRDN)vs › | $2.07B | -73.44x | N/A | N/A | N/A |
| Fortrea Holdings Inc. (FTRE)vs › | $2.03B | -0.33x | 467.98x | 502.49x | 502.49x |
| BioCryst Pharmaceuticals, Inc. (BCRX)vs › | $2.04B | 4.32x | 4.32x | 4.32x | 4.32x |
| Progyny, Inc. (PGNY)vs › | $2.04B | N/A | 166.84x | 166.84x | 166.84x |
| UroGen Pharma Ltd. (URGN)vs › | $2.04B | -3.69x | N/A | N/A | N/A |
| Aurinia Pharmaceuticals Inc. (AUPH)vs › | $2.03B | 24.23x | 24.23x | 24.23x | 24.23x |
Interest Coverage
-15.3x
Debt/Equity
0.01
Current Ratio
11.82
Formula: Interest Coverage = EBIT / Interest Expense
Reference ranges:
Note: Interest coverage should be compared with historical interest expense, operating income, and industry capital structure.
Interest Coverage = EBIT / Interest Expense
The interest coverage ratio measures operating earnings relative to interest expense.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | INTEREST COVERAGE RATIO |
|---|---|
| 2023-12-31 | -15.31x |
| 2013-12-31 | -260.16x |
| 2013-09-30 | -1789.92x |
| 2013-06-30 | -35.95x |
| 2013-03-31 | -56.13x |
| 2012-12-31 | -47.15x |
| 2012-09-30 | -38.72x |
| 2012-06-30 | -32.82x |
| 2012-03-31 | -30.69x |
| 2011-12-31 | 70.93x |
| 2011-09-30 | -26.21x |
| 2011-06-30 | -22.77x |
| 2011-03-31 | -19.91x |
| 2010-12-31 | 82.30x |
| 2010-09-30 | -26.74x |
| 2010-06-30 | -27.80x |
| 2010-03-31 | -27.91x |
| 2009-12-31 | 69.60x |
| 2009-09-30 | -204.46x |
| 2009-06-30 | -235.76x |
| 2009-03-31 | -194.66x |
| 2007-12-31 | -20.38x |
